Concepedia

John F. Reilly

JF

Statistics

Publications

37

Citations

4.9K

H-Index

31

Active since

1987

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Scripps Research Institute

United States Military Academy

The University of Texas Southwestern Medical Center

Goldfinch Bio (United States)

John F. Reilly is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

1987–2024

37

Publications

37

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Guillermo Garcia‐Manero, Hui Yang, Carlos E. Bueso‐Ramos et al. · Blood · 2007 · 460 citations

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Kurt A. Jaeckle, Matthew J. Maurer et al. · Journal of Clinical Oncology · 2009 · 354 citations · Full text

Importin β–Mediated Nuclear Import of Fibroblast Growth Factor Receptor

John F. Reilly, Pamela Maher · The Journal of Cell Biology · 2001 · 232 citations · Full text

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

Matthew J. LaMarche, Michael Acker, Andreea Argintaru et al. · Journal of Medicinal Chemistry · 2020 · 207 citations · Full text

1–5 of 37